3 Must-Own Obesity Stocks to Buy Now

Obesity drug stocks continue to explode higher.

 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Obesity drug stocks continue to explode higher.

                                                                                                     

You are receiving this email because you are subscribed to Daily Guru Trades. If you no longer wish to receive these emails, please unsubscribe here. This message is from Behind the Markets. Three Must-Own Obesity Stocks to Buy Now Obesity drug stocks continue to explode higher. Look at Eli Lilly (SYM: LLY), for example. In late July, we noted, "Oversold shares of Eli Lilly (SYM: LLY) could easily bounce higher on sales of its obesity drugs, which are still seeing considerable demand. And it could easily bounce higher with its Zepbound drug being considered for the treatment of sleep apnea." That was on July 31, as LLY traded at $795. Today, it's up to $891.68. All thanks to strong second quarter earnings and a Morgan Stanley note that LLY is its new "top pick." Even better, the firm now has a new price target of $1,106 on LLY, noting that, ""We believe LLY offers the most attractive opportunity in our coverage for upside to consensus estimates, despite the stock's outperformance." Or, look at Viking Therapeutics (SYM: VKTX). The last time we mentioned VKTX, it traded at about $49. Today, it's back to $57.16. From here, we're looking for a retest of $70. Fueling upside, the company just announced plans to start a late-stage trial for its obesity drug VK2735 later this year. "We are advancing this compound into Phase 3 development," CEO Brian Lian said, as quoted by Seeking Alpha, adding that "we are currently preparing for an end-of-phase 2 meeting with the agency, which we expect to occur later this year." There's also Novo Nordisk (SYM: NVO). After dropping to a low of about $118, the NVO stock is just starting to pivot higher. Last trading at $133.47, we'd like to see it retest $147.50 near term. Helping, Citi analysts just said NVO should be bought on its earnings pullback. "History informs us Novo pullbacks represent great buying opportunities," the firm said, as quoted by TheFly.com. The firm says only 1.4M people globally are currently on Wegovy, versus Novo's scaling ambitions in the "double to triple digit millions" and an addressable market approaching 1B by 2030.   Editor, Ian Cooper >Continue here for the latest Market News< Related Reading: 132 million Americans are DESPERATE for this New Drug...from One Tiny Company. Decades of Pent-Up Demand for this "First-Ever" Treatment Could Hand You WINDFALL PROFITS. The Wall Street Journal Reports: The "King Kong" of drugs is coming. Barron's Reports: "It will be a blockbuster." The New York Post Reports: "it's game changing." Get the name of the stock here >>> DC2 Publishing LLC 4260 NW 1st Avenue Suite # 55 Boca Raton, FL 33431 – 4264 Copyright © 2023 Daily Guru Trades, All rights reserved. You are receiving this email as part of your subscription to Daily Guru Trades. If you have any questions, please contact us at support@dailygurutrades.com. Daily Guru Trades is a newsletter offered to the public on a subscription basis. While subscribers receive the benefit of Daily Guru Trades opinions, none of the information contained therein constitutes a recommendation from Daily Guru Trades that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Daily Guru Trades may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Daily Guru Trades' past results are not necessarily indicative of future performance. Employees of Daily Guru Trades are subject to certain restrictions in transacting for their own benefit. SPECIFICALLY, EMPLOYEES ARE NOT PERMITTED TO BUY OR SELL ANY SECURITY RECOMMENDED FOR THREE (3) TRADING DAYS FOLLOWING THE ISSUE OF A REPORT OR UPDATE. Daily Guru Trades' Newsletter contains Daily Guru Trades' own opinions, and none of the information contained therein constitutes a recommendation by Daily Guru Trades that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. Daily Guru Trades' past results are not necessarily indicative of future performance. DO NOT EMAIL Daily Guru Trades SEEKING PERSONALIZED INVESTMENT ADVICE, WHICH WE CANNOT PROVIDE. The Editor's personal investing goals and risk tolerance may be substantially different from those discussed in the Newsletter and/or circumstances may have changed by the expiration of the three day restricted period, the investment actions taken by the Editor in the accounts the Editor directly or indirectly owns may vary from (and may even be contrary to) the advice and recommendations in the Newsletter.Investing involves substantial risk. Neither the Editor, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from using the Newsletter. While past performance may be analyzed in the Newsletter, past performance should not be considered indicative of future performance. No subscriber should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing the prospectus and other public filings of the issuer. To the maximum extent permitted by law, the Editor, the publisher and their respective affiliates disclaim any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations in the Newsletter prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses. The Newsletter's commentary, analysis, opinions, advice and recommendations represent the personal and subjective views of the Editor and are subject to change at any time without notice.The information provided in the Newsletter is obtained from sources which the Editor believes to be reliable. However, the Editor has not independently verified or otherwise investigated all such information. Neither the Editor, the publisher, nor any of their respective affiliates guarantees the accuracy or completeness of any such information. The Newsletter is not a solicitation or offer to buy or sell any securities. Further, the Newsletter is in no way intended to be a solicitation for any services offered by Daily Guru Trades Neither the Editor, the publisher, nor any of their respective affiliates are responsible for any errors or omissions in the Newsletter. You are receiving this email because you are subscribed to Daily Guru Trades. If you no longer wish to receive these partner emails, please unsubscribe here.